Uveitis Drugs Market to grow with a CAGR of 7.20% through 2030F
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Uveitis Drugs Market in the forecast period,
2026-2030
According
to TechSci Research report, “Global Uveitis Drugs Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2030F”, Global
Uveitis Drugs Market has valued at USD 705.30 million in 2024 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 7.20% through 2030. This can be due to collaborations and partnerships
among leading companies with a diverse approach to merge the expertise of
individual companies and to strengthen their position in the market.
The
growing aging population is a significant driver of the demand for uveitis
drugs in the Global Uveitis Drugs Market. Uveitis is an eye condition that can
affect individuals of all ages, but its prevalence tends to increase with age.
Uveitis is more commonly diagnosed in older individuals. As people age, their
immune system may undergo changes that can make them more susceptible to
autoimmune and inflammatory conditions, including uveitis. The aging process is
associated with an increased risk of age-related eye conditions, such as
cataracts, age-related macular degeneration (AMD), and diabetic retinopathy.
Some of these conditions can lead to secondary uveitis or complications that
require uveitis drugs as part of the treatment. Aging is often accompanied by
an increased prevalence of systemic diseases, including autoimmune conditions
and infections, which can trigger or exacerbate uveitis. Managing these
systemic diseases may involve the use of uveitis drugs. Elderly individuals may
have a history of corticosteroid use for various medical conditions. Long-term
corticosteroid use can lead to eye conditions such as corticosteroid-induced
glaucoma and cataracts, which may require uveitis drugs for treatment.
The
frequency of uveitis with infectious aetiologies is increasing along with the
incidence of infectious illnesses. It is mainly prevalent in poorer nations.
Around 50% of uveitis cases in India, according to the Indian Journal of
Inflammation Research, are brought on by infections. Due to viral aetiologies,
developing nations are also quite prone to ocular irritation.
In
October 2018, The U.S. Food and Drug Administration (FDA) has approved YUTIQ
(fluocinolone acetonide intravitreal implant) for the treatment of chronic
non-infectious uveitis affecting the posterior segment of the eye, according to
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated
to developing and commercializing innovative ophthalmic products. YUTIQ is a
non-bioerodible intravitreal micro-insert in a drug delivery system containing
0.18 mg fluocinolone acetonide that is intended to release steadily over a
36-month period. It uses the company's Durasert drug delivery technology. YUTIQ
is provided in a preloaded, single-dose sterile applicator that may be used to
deliver the medication at a doctor's office. The prevalence of recurrent
uveitis flares was considerably lower with YUTIQ in clinical studies compared
to placebo, and the most frequent side effects were cataract formation and a
rise in intraocular pressure (IOP).
Browse
over XX market data Figures and spread through 110
Pages and an in-depth TOC on "Uveitis Drugs Market”
Limited
treatment options can be a challenge in the Global Uveitis Drugs Market.
Uveitis is a complex and heterogeneous condition with various underlying causes
and manifestations. Uveitis encompasses several distinct forms, including
anterior, intermediate, posterior, and panuveitis, each with its unique
characteristics and underlying causes. Treatment approaches need to be tailored
to the specific type of uveitis, and this diversity can make it challenging to
develop a one-size-fits-all treatment. Uveitis can be associated with a wide
range of underlying causes, including infections, autoimmune diseases, and
idiopathic (unknown) factors. Identifying and addressing the underlying cause
is crucial for effective treatment. In some cases, determining the cause can be
challenging.
Global
Uveitis Drugs Market segmentation is based on treatment type, disease
type, cause, distribution channel, region and company.
Based
on cause, in 2024, the Global Uveitis Drugs Market largest share was held by
Non-infectious segment and is predicted to continue expanding over the coming
years. Non-infectious uveitis, also known as autoimmune uveitis, is a
form of uveitis that is primarily caused by an autoimmune response. This type
of uveitis is more common than infectious uveitis in many regions, including
North America and Europe. Non-infectious uveitis often has a chronic or
recurrent nature, requiring long-term treatment and management. This can result
in a higher demand for uveitis drugs for this segment. They can be challenging
to manage, and patients may require a combination of drugs to control
inflammation and prevent recurrences. This complexity can lead to a higher
volume of drug usage.
Based
on Region, Asia-pacific region to fastest growth in the Global
Uveitis Drugs Market. The Asia-Pacific region has seen a rise in the incidence
of uveitis, which can be attributed to factors such as changes in lifestyle,
environmental factors, and improved diagnostic capabilities. As more cases are
diagnosed, the demand for uveitis drugs is growing. Like many parts of the
world, the Asia-Pacific region is experiencing demographic shifts, with a
growing aging population. Uveitis is more common in older individuals, so the
increase in the elderly population contributes to higher uveitis prevalence.
Improvements in healthcare infrastructure and increased awareness about eye
health have led to earlier detection and treatment of eye conditions, including
uveitis. The growing middle-class population in the Asia-Pacific region has
increased the affordability of healthcare services, including specialized eye
care. This has encouraged more people to seek treatment for uveitis.
Some
of the major companies operating in the Global Uveitis Drugs Market include:
- Allergan Inc.
- Bausch & Lomb Incorporated
- Santen Pharmaceutical Co. Ltd
- AbbVie Inc.
- Novartis AG
- Eyegate Pharmaceuticals Inc.
- Regeneron Pharmaceuticals
- Eyepoint pharmaceuticals Inc.
- Alimera Sciences Inc.
Download Free Sample Report
Customers
can also request 10% free customization on this report
“North
America is expected to drive significant demand for uveitis drugs, fueled by a
growing patient population and advancements in treatment options. The presence
of well-established pharmaceutical companies, along with increasing investments
in research and development, is accelerating market growth. These companies are
dedicated to improving patient outcomes through innovative therapies. A
competitive landscape and rising awareness about early diagnosis and treatment
are key factors boosting demand. With ongoing advancements in ophthalmic care
and supportive regulatory frameworks, the global uveitis drugs market is
projected to witness substantial expansion during the forecast period, offering
improved treatment options for patients" said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
“Uveitis
Drugs Market, Segmented by Treatment Type (Analgesics, Antibiotics, Antifungal,
Antivirals, Corticosteroids, Cycloplegic Agents, Immunosuppressant, Monoclonal
Antibodies) by Disease Type (Anterior Uveitis, Intermediate Uveitis,
Panuveitis, Posterior Uveitis), by Cause (Infectious, Noninfectious), by
Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail
Pharmacies), by region, and Competition 2020-203F” evaluated
the future growth potential of Global Uveitis Drugs Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Uveitis Drugs Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com